On August 5, 2022 Pillar Biosciences, the leader in Decision Medicine, which develops and distributes next-generation sequencing (NGS) products and technologies to localize testing and reduce time to treatment initiation and overall testing costs, reported that Randy Pritchard, Chief Executive Officer, will participate in the "Liquid Biopsy in Clinical Practice" panel discussion at the 2022 UBS Genomics 2.0 and MedTech Innovations Summit in Dana Point, California on Tuesday, August 9, 2022 at 7:00pm Eastern Time / 4:00pm Pacific Time (Press release, Pillar Biosciences, AUG 5, 2022, View Source [SID1234617708]). Randy Pritchard and Vincent Ricci, Chief Financial Officer, will also participate in investor meetings at the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!